Prevalence of hearing loss in pseudohypoparathyroidism.
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
29
04
2024
accepted:
26
07
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
The main clinical features of pseudohypoparathyroidism (PHP)/inactivating parathyroid hormone/parathyroid hormone-related protein signaling disorders (iPPSD), including parathyroid hormone (PTH) resistance, brachydactyly and short stature, develop during middle and late childhood. Very few studies have addressed hearing loss in PHP/iPPSD patients, and these studies have yielded widely divergent conclusions. The aim of our study was to assess hearing and determine the predictive factors of hearing loss in patients with PHP/iPPSD. Our retrospective cohort study was conducted between March 2019 and May 2020 in the Otolaryngology Department and the calcium phosphate reference center for rare diseases in Bicêtre Paris-Saclay Hospital, France. We retrospectively collected data from patients with PHP/iPPSDs (age, sex, genetic mutations, height, body mass index (BMI), PTH resistance, presence or absence of ectopic ossifications and brachydactyly). All patients underwent auditory investigations, including tonal and vocal audiometry. The primary outcome was the pure tone average (PTA). The PTA was compared with the norm according to the International Organization for Standardization. Hearing loss was defined as a PTA ≥ 20 db. The median age of the patients was 15.6 years [9.5, 28.5]. Thirty-six patients were diagnosed with iPPSD2, and eight were diagnosed with iPPSD3. Twenty-six of them (59%) were female. Hearing impairment was confirmed in 17 patients (39%). The mean PTA and the mean SRT of the deaf ears were 40 ± 26 db and 31 ± 14 db. The mean difference in the PTA between the patients and the normal controls was 11.4 db (p = 0.00002). Short stature and the presence of ectopic ossifications were two significant predictive factors of hearing loss (p = 0.009 and p = 0.03, respectively). Sex, BMI, PTH resistance, mutation category and brachydactyly were not associated with an increased risk of hearing loss (p = 0.19, p = 0.41, p = 0.13, p = 0.50, p = 0.19, respectively). Our study confirmed the frequency of hearing loss in patients with PHP/iPPSD disease (prevalence = 39%). A diagnosis of PHP/iPPSD should trigger auditory investigations and follow-up, especially when short stature and/or ectopic ossifications are present.
Sections du résumé
BACKGROUND
BACKGROUND
The main clinical features of pseudohypoparathyroidism (PHP)/inactivating parathyroid hormone/parathyroid hormone-related protein signaling disorders (iPPSD), including parathyroid hormone (PTH) resistance, brachydactyly and short stature, develop during middle and late childhood. Very few studies have addressed hearing loss in PHP/iPPSD patients, and these studies have yielded widely divergent conclusions. The aim of our study was to assess hearing and determine the predictive factors of hearing loss in patients with PHP/iPPSD.
METHODS
METHODS
Our retrospective cohort study was conducted between March 2019 and May 2020 in the Otolaryngology Department and the calcium phosphate reference center for rare diseases in Bicêtre Paris-Saclay Hospital, France. We retrospectively collected data from patients with PHP/iPPSDs (age, sex, genetic mutations, height, body mass index (BMI), PTH resistance, presence or absence of ectopic ossifications and brachydactyly). All patients underwent auditory investigations, including tonal and vocal audiometry. The primary outcome was the pure tone average (PTA). The PTA was compared with the norm according to the International Organization for Standardization. Hearing loss was defined as a PTA ≥ 20 db.
RESULTS
RESULTS
The median age of the patients was 15.6 years [9.5, 28.5]. Thirty-six patients were diagnosed with iPPSD2, and eight were diagnosed with iPPSD3. Twenty-six of them (59%) were female. Hearing impairment was confirmed in 17 patients (39%). The mean PTA and the mean SRT of the deaf ears were 40 ± 26 db and 31 ± 14 db. The mean difference in the PTA between the patients and the normal controls was 11.4 db (p = 0.00002). Short stature and the presence of ectopic ossifications were two significant predictive factors of hearing loss (p = 0.009 and p = 0.03, respectively). Sex, BMI, PTH resistance, mutation category and brachydactyly were not associated with an increased risk of hearing loss (p = 0.19, p = 0.41, p = 0.13, p = 0.50, p = 0.19, respectively).
CONCLUSION
CONCLUSIONS
Our study confirmed the frequency of hearing loss in patients with PHP/iPPSD disease (prevalence = 39%). A diagnosis of PHP/iPPSD should trigger auditory investigations and follow-up, especially when short stature and/or ectopic ossifications are present.
Identifiants
pubmed: 39267114
doi: 10.1186/s13023-024-03299-3
pii: 10.1186/s13023-024-03299-3
doi:
Substances chimiques
Parathyroid Hormone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
339Informations de copyright
© 2024. The Author(s).
Références
Linglart A, Levine MA, Jüppner H, Pseudohypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47(4):865–88.
doi: 10.1016/j.ecl.2018.07.011
pubmed: 30390819
pmcid: 7305568
Linglart A. GNAS-related loss of function disorders and the role of imprinting. Horm Res Paediatr. 2013;79:119–29.
doi: 10.1159/000348516
pubmed: 23548772
Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf). 2016;84(6):904–11.
doi: 10.1111/cen.12948
pubmed: 26387561
Thiele S, Mantovani G, Barlier A, Boldrin V, Bordogna P, De Sanctis L, et al. From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network. Eur J Endocrinol déc. 2016;175(6):P1–17.
doi: 10.1530/EJE-16-0107
Curley KL, Kahanda S, Perez KM, Malow BA, Shoemaker AH. Obstructive sleep apnea and otolaryngologic manifestations in children with pseudohypoparathyroidism. Horm Res Paediatr. 2018;89(3):178–83.
doi: 10.1159/000486715
pubmed: 29455209
Koch T, Lehnhardt E, Böttinger H, Pfeuffer T, Palm D, Fischer B, et al. Sensorineural hearing loss owing to deficient G proteins in patients with pseudohypoparathyroidism: results of a multicentre study. Eur J Clin Invest août. 1990;20(4):416–21.
doi: 10.1111/j.1365-2362.1990.tb01879.x
Garty BZ, Daliot D, Kauli R, Arie R, Grosman J, Nitzan M, et al. Hearing impairment in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Isr J Med Sci août. 1994;30(8):587–91.
Shoemaker AH, Jüppner H. Nonclassic features of pseudohypoparathyroidism type 1A. Curr Opin Endocrinol Diabetes Obes févr. 2017;24(1):33–8.
doi: 10.1097/MED.0000000000000306
Elli FM, Pereda A, Linglart A, Perez de Nanclares G, Mantovani G. Parathyroid hormone resistance syndromes - inactivating PTH/PTHrP signaling disorders (iPPSDs). Best Pract Res Clin Endocrinol Metab. 2018;32(6):941–54.
doi: 10.1016/j.beem.2018.09.008
pubmed: 30665554
Herpin N. La taille des hommes: son incidence sur la vie en couple et la carrière professionnelle. In: Economie et Statistiques. 2003 éd. p. 361 pp. 71–90.
Chalak S, Kale A, Deshpande VK, Biswas DA. Establishment of normative data for monaural recordings of Auditory Brainstem Response and its application in Screening patients with hearing loss: a Cohort Study. J Clin Diagn Res JCDR déc. 2013;7(12):2677–9.
Veillon F, Riehm S, Eliezer M, Karch-Georges A, Charpiot A, Fleury A, et al. Present and future of the labyrinth imaging: focus on the use of T2-weighted and contrast-enhanced delayed FLAIR (1 h) sequences. J Vestib Res Equilib Orientat. 2021;31(4):251–9.
doi: 10.3233/VES-200796